EquitySector - HealthcareVery High Risk
Direct
NAV (30-Oct-24)
Returns (Since Inception)
Fund Size
₹2,794 Cr
Expense Ratio
0.48%
ISIN
INF769K01ED6
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
02 Jun 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+54.01%
+55.55% (Cat Avg.)
3 Years
+20.48%
+19.48% (Cat Avg.)
5 Years
+31.16%
+27.86% (Cat Avg.)
Since Inception
+25.02%
— (Cat Avg.)
Equity | ₹2,783.64 Cr | 99.64% |
Others | ₹9.97 Cr | 0.36% |
All Holdings
Equity
Debt & Others
Name | Type | Amount | Holdings |
---|---|---|---|
Sun Pharmaceuticals Industries Ltd | Equity | ₹346.31 Cr | 12.40% |
Aurobindo Pharma Ltd | Equity | ₹233.14 Cr | 8.35% |
Cipla Ltd | Equity | ₹196.01 Cr | 7.02% |
Dr Reddy's Laboratories Ltd | Equity | ₹177.56 Cr | 6.36% |
Apollo Hospitals Enterprise Ltd | Equity | ₹164.43 Cr | 5.89% |
Glenmark Pharmaceuticals Ltd | Equity | ₹154.32 Cr | 5.52% |
Lupin Ltd | Equity | ₹141.57 Cr | 5.07% |
Divi's Laboratories Ltd | Equity | ₹127.05 Cr | 4.55% |
Gland Pharma Ltd | Equity | ₹119.06 Cr | 4.26% |
Krishna Institute of Medical Sciences Ltd | Equity | ₹111.85 Cr | 4.00% |
Torrent Pharmaceuticals Ltd | Equity | ₹102.79 Cr | 3.68% |
Suven Pharmaceuticals Ltd | Equity | ₹100.12 Cr | 3.58% |
Syngene International Ltd | Equity | ₹86.34 Cr | 3.09% |
Mankind Pharma Ltd | Equity | ₹79.92 Cr | 2.86% |
J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹76.97 Cr | 2.76% |
Fortis Healthcare Ltd | Equity | ₹71.9 Cr | 2.57% |
Zydus Lifesciences Ltd | Equity | ₹61.27 Cr | 2.19% |
Strides Pharma Science Ltd | Equity | ₹60.48 Cr | 2.17% |
Alkem Laboratories Ltd | Equity | ₹60.27 Cr | 2.16% |
Ipca Laboratories Ltd | Equity | ₹49.37 Cr | 1.77% |
Wockhardt Ltd | Equity | ₹47.31 Cr | 1.69% |
Dr. Lal PathLabs Ltd | Equity | ₹39.06 Cr | 1.40% |
Emcure Pharmaceuticals Ltd | Equity | ₹28.76 Cr | 1.03% |
Biocon Ltd | Equity | ₹27.74 Cr | 0.99% |
Max Healthcare Institute Ltd Ordinary Shares | Equity | ₹26.62 Cr | 0.95% |
Neogen Chemicals Ltd | Equity | ₹21.28 Cr | 0.76% |
Sanofi India Ltd | Equity | ₹18.9 Cr | 0.68% |
Ajanta Pharma Ltd | Equity | ₹14.75 Cr | 0.53% |
Sanofi Consumer Healthcare India Ltd | Equity | ₹13.53 Cr | 0.48% |
SRF Ltd | Equity | ₹12.57 Cr | 0.45% |
Treps | Cash - Repurchase Agreement | ₹12.54 Cr | 0.45% |
Natco Pharma Ltd | Equity | ₹12.4 Cr | 0.44% |
Net Receivables / (Payables) | Cash | ₹-2.79 Cr | 0.10% |
Mirae Asset Liquid Dir Gr | Mutual Fund - Open End | ₹0.22 Cr | 0.01% |
Large Cap Stocks
44.94%
Mid Cap Stocks
35.71%
Small Cap Stocks
17.48%
Equity Sector
Debt & Others
Sector | Amount | Holdings |
---|---|---|
Healthcare | ₹2,749.8 Cr | 98.43% |
Basic Materials | ₹33.84 Cr | 1.21% |
Standard Deviation
This fund
16.01%
Cat. avg.
15.87%
Lower the better
Sharpe Ratio
This fund
0.86
Cat. avg.
0.85
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.55
Higher the better
Since July 2018
ISIN INF769K01ED6 | Expense Ratio 0.48% | Exit Load 1.00% | Fund Size ₹2,794 Cr | Age 6 years 4 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.
Fund name | Expense Ratio | Exit Load | Fund size | 1Y |
---|---|---|---|---|
Motilal Oswal S&P BSE Healthcare ETF Very High Risk | 0.2% | - | ₹21.04 Cr | 57.8% |
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk | 0.9% | 1.0% | ₹888.27 Cr | 52.1% |
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk | 2.3% | 1.0% | ₹888.27 Cr | 50.0% |
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk | 0.2% | - | ₹39.61 Cr | 53.9% |
ITI Pharma and Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹201.94 Cr | 59.4% |
ITI Pharma and Healthcare Fund Regular Growth Very High Risk | 2.4% | 1.0% | ₹201.94 Cr | 56.4% |
Mirae Asset Healthcare Fund Direct Growth Very High Risk | 0.5% | 1.0% | ₹2793.61 Cr | 54.0% |
Mirae Asset Healthcare Fund Regular Growth Very High Risk | 1.9% | 1.0% | ₹2793.61 Cr | 51.7% |
Nippon India Nifty Pharma ETF Very High Risk | 0.2% | - | ₹851.53 Cr | 52.0% |
Axis NIFTY Healthcare ETF Very High Risk | 0.3% | - | ₹19.51 Cr | 52.8% |
Total AUM
₹1,97,338 Cr
Address
Unit No. 606, 6th Floor, Mumbai, 400 098
Your principal amount will be at Very High Risk